Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate
- PMID: 2971382
- DOI: 10.1016/8756-3282(88)90001-4
Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate
Abstract
Increased bone resorption (BR) and increased renal tubular reabsorption of calcium (TRCa) may both be involved in the pathogenesis of hypercalcemia of malignancy (HM). We have evaluated the relative importance of these two mechanisms in 33 patients with HM after extracellular volume expansion and after single infusion of clodronate (C12MDP: 500 mg iv over 8 h). The fasting urine Ca/creatinine ratio was taken as an index of BR (BRI). An index of TRCa was calculated (TRCaI) from a nomogram based on the relationship between urine Ca excretion per unit of glomerular filtration rate and plasma Ca (PCa). Mean (+/- SEM) PCa fell from 3.29 +/- 0.07 to 2.69 +/- 0.05 mmol/l three days after C12MDP (n = 33, p less than 0.001), a response similar to that obtained with repeated daily iv injections of 500 to 1000 mg C12MDP. The pathogenesis of hypercalcemia varied according to the type of neoplasm. BRI was the highest in multiple myeloma and breast tumors. TRCaI was markedly increased in squamous-cells lung, bladder, kidney and liver carcinomas, reaching levels observed in primary hyperparathyroidism. TRCaI was normal in most cases of multiple myeloma. Breast tumors appeared to be heterogeneous with respect to TRCaI. The fall in PCa in response to a single infusion of C12MDP was usually most marked in cancer patients with elevated BRI and normal TRCaI. It was very modest in patients with high TRCaI and slightly elevated BRI. In conclusion, this study confirms that stimulation of bone resorption is not the only mechanism of the maintenance of hypercalcemia of malignancy.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia.Bone. 1991;12(1):47-56. doi: 10.1016/8756-3282(91)90055-n. Bone. 1991. PMID: 2054236
-
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.J Clin Endocrinol Metab. 1999 Oct;84(10):3545-50. doi: 10.1210/jcem.84.10.6026. J Clin Endocrinol Metab. 1999. PMID: 10522993 Clinical Trial.
-
Management of hypercalcemia in relation to pathophysiology.Bone. 1987;8 Suppl 1:S29-33. Bone. 1987. PMID: 2825740 Review.
-
Use of clodronate and calcitonin in hypercalcemia due to malignancy.Recent Results Cancer Res. 1989;116:40-5. doi: 10.1007/978-3-642-83668-8_3. Recent Results Cancer Res. 1989. PMID: 2527399 Review.
-
Treatment of the hypercalcaemia of malignancy with intravenous clodronate.Bone. 1987;8 Suppl 1:S43-51. Bone. 1987. PMID: 2961354
Cited by
-
Clodronate in hypercalcemia of malignancy.Calcif Tissue Int. 1990;46 Suppl:S20-5. doi: 10.1007/BF02553289. Calcif Tissue Int. 1990. PMID: 2137362 Review.
-
Bisphosphonates and the treatment of bone disease in the elderly.Drugs Aging. 1996 Feb;8(2):113-26. doi: 10.2165/00002512-199608020-00005. Drugs Aging. 1996. PMID: 8845585 Review.
-
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.Br J Cancer. 1996 May;73(9):1074-9. doi: 10.1038/bjc.1996.207. Br J Cancer. 1996. PMID: 8624266 Free PMC article. Clinical Trial.
-
New bisphosphonates in the treatment of bone diseases.Drugs Aging. 1999 Oct;15(4):285-96. doi: 10.2165/00002512-199915040-00004. Drugs Aging. 1999. PMID: 10582775 Review.
-
Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.Clin Cases Miner Bone Metab. 2009 May;6(2):163-8. Clin Cases Miner Bone Metab. 2009. PMID: 22461168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources